|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
| ||||||||||||||||||||
Files in this Data Supplement:
Fig. S1. Alignment of human and Xenopus Galntl-1. Indicated are the transmembrane domain (blue), the catalytic domain (red) that consists of a GT1 and a GalNac-T subdomain (orange) and contains conserved amino acids implicated in substrate binding and catalysis (yellow), and the Ricin domain (green).
Fig. S2. Effect of OP-1, dnFGFR4, dnTCF3 or dnALK-4 on the xGalntl-1 phenotype. (A-E) Stage 40 embryos microinjected with 200 pg xGalntl-1 mRNA alone (A) or together with 200 pg OP-1 (B), dnFGFR-4 (C), dnTCF-3 (D) or dnAlk-4 (E). (F) RT-PCR analysis of ectodermal explants obtained from sibling embryos at stage 9 and analyzed at stage 25.
Fig. S3. Xenopus Galtnl-1 completely abolishes the ventralizing activity of Alk-3, Alk-6 and BMPR-II. (A) Stage 33 uninjected control embryo. (B) RT-PCR analyses of ectodermal explants from embryos microinjected with 200 pg mRNA encoding the indicated BMP type I and type receptors. (C-H) Stage 33 embryos microinjected with 200 pg mRNA encoding Alk-3 (C,D), Alk-6 (E,F) or BMPR-II (G,H) alone (C,E,G), or together with 200 pg xGalntl-1 mRNA (D,F,G).
| ||||||||||||||||||||
